Suppr超能文献

肥胖增强了非基因组雌激素受体与PI3K/Akt和MAPK信号通路的相互作用,从而促进乳腺癌进展的体外检测。

Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression.

作者信息

Bowers Laura W, Cavazos David A, Maximo Ilane X F, Brenner Andrew J, Hursting Stephen D, deGraffenried Linda A

出版信息

Breast Cancer Res. 2013;15(4):R59. doi: 10.1186/bcr3453.

Abstract

INTRODUCTION

Epidemiological and clinical studies indicate that obesity is associated with a worse postmenopausal breast cancer prognosis and an increased risk of endocrine therapy resistance. However, the mechanisms mediating these effects remain poorly understood. Here we investigate the molecular pathways by which obesity-associated circulating factors in the blood enhance estrogen receptor alpha (ERα) positive breast cancer cell viability and growth.

METHODS

Blood serum was collected from postmenopausal breast cancer patients and pooled by body mass index (BMI) category (Control: 18.5 to 24.9 kg/m²; Obese: ≥30.0 kg/m²). The effects of patient sera on MCF-7 and T47D breast cancer cell viability and growth were examined by MTT and colony formation assays, respectively. Insulin-like growth factor receptor 1(IGF-1R), Akt, and ERK1/2 activation and genomic ERα activity were assessed to determine their possible contribution to obese patient sera-induced cell viability and growth. To further define the relative contribution of these signaling pathways, cells grown in patient sera were treated with various combinations of ERα, PI3K/Akt and MAPK targeted therapies. Comparisons between cells exposed to different experimental conditions were made using one-way analysis of variance (ANOVA) and Student's t test.

RESULTS

Cells grown in media supplemented with obese patient sera displayed greater cell viability and growth as well as IGF-1R, Akt and ERK1/2 activation relative to control sera. Despite the lack of a significant difference in genomic ERα activity following growth in obese versus control patient sera, we observed a dramatic reduction in cell viability and growth after concurrent inhibition of the ERα and PI3K/Akt signaling pathways. Further, we demonstrated that ERα inhibition was sufficient to attenuate obese serum-induced Akt and ERK1/2 activation. Together, these data suggest that obesity promotes greater ERα positive breast cancer cell viability and growth through enhanced crosstalk between nongenomic ERα signaling and the PI3K/Akt and MAPK pathways.

CONCLUSIONS

Circulating factors in the serum of obese postmenopausal women stimulate ERα positive breast cancer cell viability and growth by facilitating non-genomic ERα crosstalk with the PI3K/Akt and MAPK signaling pathways. These findings provide valuable insight into one mechanism by which obesity may promote ERα positive postmenopausal breast cancer progression and endocrine therapy resistance.

摘要

引言

流行病学和临床研究表明,肥胖与绝经后乳腺癌预后较差以及内分泌治疗耐药风险增加有关。然而,介导这些效应的机制仍知之甚少。在此,我们研究血液中与肥胖相关的循环因子增强雌激素受体α(ERα)阳性乳腺癌细胞活力和生长的分子途径。

方法

收集绝经后乳腺癌患者的血清,并按体重指数(BMI)类别进行汇总(对照组:18.5至24.9kg/m²;肥胖组:≥30.0kg/m²)。分别通过MTT和集落形成试验检测患者血清对MCF-7和T47D乳腺癌细胞活力和生长的影响。评估胰岛素样生长因子受体1(IGF-1R)、Akt和ERK1/2的激活以及基因组ERα活性,以确定它们对肥胖患者血清诱导的细胞活力和生长的可能贡献。为了进一步明确这些信号通路的相对贡献,用ERα、PI3K/Akt和MAPK靶向治疗的各种组合处理在患者血清中生长的细胞。使用单因素方差分析(ANOVA)和学生t检验对暴露于不同实验条件的细胞进行比较。

结果

与对照血清相比,在补充肥胖患者血清的培养基中生长的细胞表现出更高的细胞活力和生长以及IGF-1R、Akt和ERK1/2激活。尽管在肥胖患者血清与对照患者血清中生长后基因组ERα活性没有显著差异,但我们观察到同时抑制ERα和PI3K/Akt信号通路后细胞活力和生长显著降低。此外,我们证明ERα抑制足以减弱肥胖血清诱导的Akt和ERK1/2激活。总之,这些数据表明肥胖通过增强非基因组ERα信号与PI3K/Akt和MAPK通路之间的串扰促进ERα阳性乳腺癌细胞的活力和生长。

结论

肥胖绝经后女性血清中的循环因子通过促进非基因组ERα与PI3K/Akt和MAPK信号通路的串扰来刺激ERα阳性乳腺癌细胞的活力和生长。这些发现为肥胖可能促进ERα阳性绝经后乳腺癌进展和内分泌治疗耐药的一种机制提供了有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12e/3978844/f9b0ada44816/bcr3453-1.jpg

相似文献

3
Activation of G protein-coupled receptor 30 by thiodiphenol promotes proliferation of estrogen receptor α-positive breast cancer cells.
Chemosphere. 2017 Feb;169:204-211. doi: 10.1016/j.chemosphere.2016.11.066. Epub 2016 Nov 20.
7
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Int J Cancer. 2015 Aug 1;137(3):686-97. doi: 10.1002/ijc.29404. Epub 2015 Jan 8.
8
Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways.
PLoS One. 2014 Mar 11;9(3):e91245. doi: 10.1371/journal.pone.0091245. eCollection 2014.
9
Luteolin inhibits proliferation induced by IGF-1 pathway dependent ERα in human breast cancer MCF-7 cells.
Asian Pac J Cancer Prev. 2012;13(4):1431-7. doi: 10.7314/apjcp.2012.13.4.1431.

引用本文的文献

1
Obesity, white adipose tissue and cancer.
FEBS J. 2025 May;292(9):2189-2207. doi: 10.1111/febs.17312. Epub 2024 Nov 4.
2
Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation.
Adv Exp Med Biol. 2024;1460:767-819. doi: 10.1007/978-3-031-63657-8_26.
3
Obesity, dysbiosis and inflammation: interactions that modulate the efficacy of immunotherapy.
Front Immunol. 2024 Aug 26;15:1444589. doi: 10.3389/fimmu.2024.1444589. eCollection 2024.
4
Role of microRNAs in triple‑negative breast cancer and new therapeutic concepts (Review).
Oncol Lett. 2024 Jul 11;28(3):431. doi: 10.3892/ol.2024.14565. eCollection 2024 Sep.
5
Editorial: Adipokines and hormone-dependent cancers.
Front Endocrinol (Lausanne). 2023 Dec 1;14:1340171. doi: 10.3389/fendo.2023.1340171. eCollection 2023.
7
Obesity and endocrine-related cancer: The important role of IGF-1.
Front Endocrinol (Lausanne). 2023 Jan 23;14:1093257. doi: 10.3389/fendo.2023.1093257. eCollection 2023.
9
An IGF-1R-mTORC1-SRPK2 signaling Axis contributes to FASN regulation in breast cancer.
BMC Cancer. 2022 Sep 12;22(1):976. doi: 10.1186/s12885-022-10062-z.
10
Modulation of Breast Cancer Cell FASN Expression by Obesity-Related Systemic Factors.
Breast Cancer (Auckl). 2022 Aug 22;16:11782234221111374. doi: 10.1177/11782234221111374. eCollection 2022.

本文引用的文献

1
Metformin and breast cancer risk: a meta-analysis and critical literature review.
Breast Cancer Res Treat. 2012 Oct;135(3):639-46. doi: 10.1007/s10549-012-2170-x. Epub 2012 Jul 31.
2
Diabetes, metformin, and breast cancer in postmenopausal women.
J Clin Oncol. 2012 Aug 10;30(23):2844-52. doi: 10.1200/JCO.2011.39.7505. Epub 2012 Jun 11.
4
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
Cancer Lett. 2012 Oct 1;323(1):77-87. doi: 10.1016/j.canlet.2012.03.034. Epub 2012 Apr 3.
6
Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010.
JAMA. 2012 Feb 1;307(5):491-7. doi: 10.1001/jama.2012.39. Epub 2012 Jan 17.
7
Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.
J Clin Oncol. 2012 Jan 10;30(2):164-71. doi: 10.1200/JCO.2011.36.2723. Epub 2011 Dec 12.
8
Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity.
Endocr Relat Cancer. 2012 Feb 13;19(1):57-68. doi: 10.1530/ERC-11-0213. Print 2012 Feb.
9
Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.
Breast Cancer Res Treat. 2012 Feb;131(3):925-31. doi: 10.1007/s10549-011-1874-7. Epub 2011 Nov 13.
10
Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins.
Cancer Invest. 2011 Nov;29(9):585-93. doi: 10.3109/07357907.2011.616252. Epub 2011 Sep 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验